product summary
company name :
Cell Signaling Technology
product type :
antibody
product name :
HER2/ErbB2 (29D8) Rabbit mAb
catalog :
2165S
quantity :
100 ul
price :
235 USD
clonality :
monoclonal
host :
rabbit
reactivity :
, human, mouse, rat
application :
western blot, immunohistochemistry, immunocytochemistry, immunoprecipitation, flow cytometry, immunohistochemistry - paraffin section
more info or order :
Cell Signaling Technology product webpage
citations: 20
Published Application/Species/DilutionReference
  • western blot; human; 1:100
Hofmann B, Schlüter L, Lange P, Mercanoglu B, Ewald F, Fölster A, et al. COSMC knockdown mediated aberrant O-glycosylation promotes oncogenic properties in pancreatic cancer. Mol Cancer. 2015;14:109 pubmed publisher
  • immunohistochemistry - paraffin section; human; 1:25
Jäger W, Xue H, Hayashi T, Janssen C, Awrey S, Wyatt A, et al. Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies. Oncotarget. 2015;6:21522-32 pubmed
  • western blot; human
Yoo J, Kim T, Kong S, Lee J, Choi W, Kim K, et al. Role of Mig-6 in hepatic glucose metabolism. J Diabetes. 2015;: pubmed publisher
  • western blot; human; fig 4
Yang L, Li Y, Bhattacharya A, Zhang Y. Inhibition of ERBB2-overexpressing Tumors by Recombinant Human Prolidase and Its Enzymatically Inactive Mutant. EBioMedicine. 2015;2:396-405 pubmed
  • western blot; human
  • immunocytochemistry; human
Asp N, Pust S, Sandvig K. Flotillin depletion affects ErbB protein levels in different human breast cancer cells. Biochim Biophys Acta. 2014;1843:1987-96 pubmed publisher
  • western blot; human; fig 2
Brouxhon S, Kyrkanides S, Teng X, O'Banion M, Clarke R, Byers S, et al. Soluble-E-cadherin activates HER and IAP family members in HER2+ and TNBC human breast cancers. Mol Carcinog. 2014;53:893-906 pubmed publisher
  • western blot; human
Hong Y, Kim J, Pectasides E, Fox C, Hong S, Ma Q, et al. Src mutation induces acquired lapatinib resistance in ERBB2-amplified human gastroesophageal adenocarcinoma models. PLoS ONE. 2014;9:e109440 pubmed publisher
  • immunocytochemistry; mouse; 1:200
  • western blot; mouse; 1:1000
Harmelink C, Peng Y, Debenedittis P, Chen H, Shou W, Jiao K. Myocardial Mycn is essential for mouse ventricular wall morphogenesis. Dev Biol. 2013;373:53-63 pubmed publisher
  • immunocytochemistry; human; 1:150
Lindberg K, Helguero L, Omoto Y, Gustafsson J, Haldosén L. Estrogen receptor β represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity. Breast Cancer Res. 2011;13:R43 pubmed publisher
Khalil H, Langdon S, Kankia I, Bown J, Deeni Y. NRF2 Regulates HER2 and HER3 Signaling Pathway to Modulate Sensitivity to Targeted Immunotherapies. Oxid Med Cell Longev. 2016;2016:4148791 pubmed publisher
Papadakis E, Barker C, Syed H, Reeves T, Schwaiger S, Stuppner H, et al. The Bag-1 inhibitor, Thio-2, reverses an atypical 3D morphology driven by Bag-1L overexpression in a MCF-10A model of ductal carcinoma in situ. Oncogenesis. 2016;5:e215 pubmed publisher
Li Z, Jia L, Wang J, Wu X, Shi G, Lu C, et al. Discovery of novel 17-phenylethylaminegeldanamycin derivatives as potent Hsp90 inhibitors. Chem Biol Drug Des. 2015;85:181-8 pubmed publisher
Jørgensen M, Bæk R, Varming K. Potentials and capabilities of the Extracellular Vesicle (EV) Array. J Extracell Vesicles. 2015;4:26048 pubmed publisher
Milano G, Raucci A, Scopece A, Daniele R, Guerrini U, Sironi L, et al. Doxorubicin and trastuzumab regimen induces biventricular failure in mice. J Am Soc Echocardiogr. 2014;27:568-79 pubmed publisher
Wattenberg M, Kwilas A, Gameiro S, Dicker A, Hodge J. Expanding the use of monoclonal antibody therapy of cancer by using ionising radiation to upregulate antibody targets. Br J Cancer. 2014;110:1472-80 pubmed publisher
González-Vallinas M, Molina S, Vicente G, Sánchez-Martínez R, Vargas T, García-Risco M, et al. Modulation of estrogen and epidermal growth factor receptors by rosemary extract in breast cancer cells. Electrophoresis. 2014;35:1719-27 pubmed publisher
Slanina H, Mündlein S, Hebling S, Schubert-Unkmeir A. Role of epidermal growth factor receptor signaling in the interaction of Neisseria meningitidis with endothelial cells. Infect Immun. 2014;82:1243-55 pubmed publisher
Tardáguila M, Mira E, Garcia-Cabezas M, Feijoo A, Quintela-Fandino M, Azcoitia I, et al. CX3CL1 promotes breast cancer via transactivation of the EGF pathway. Cancer Res. 2013;73:4461-73 pubmed publisher
Perez-Pinera P, Ousterout D, Brunger J, Farin A, Glass K, Guilak F, et al. Synergistic and tunable human gene activation by combinations of synthetic transcription factors. Nat Methods. 2013;10:239-42 pubmed publisher
Jørgensen M, Bæk R, Pedersen S, Søndergaard E, Kristensen S, Varming K. Extracellular Vesicle (EV) Array: microarray capturing of exosomes and other extracellular vesicles for multiplexed phenotyping. J Extracell Vesicles. 2013;2: pubmed publisher
product information
SKU :
2165S
Product-Name :
HER2/ErbB2 (29D8) Rabbit mAb
Size :
100 ul
Price-(USD) :
235 USD
Species-x-Reactivity :
H, (M, R)
Applications :
Flow cytometry
Product-Category :
RTK
Shipping-Temp :
AMBIENT
Storage-Temp :
-20°C
Product-Type :
Monoclonal Antibody
MW :
185 kDa
Host :
Rabbit
Target :
HER2/ErbB2
Primary-Protein :
HER2
Alt-Names :
CD340,ERBB2,HER-2,HER-2/neu,HER2,MLN 19,MLN19,Metastatic lymph node gene 19 protein,NEU,NGL,Proto-oncogene Neu,Proto-oncogene c-ErbB-2,Receptor tyrosine-protein kinase erbB-2,TKR1,Tyrosine kinase-type cell surface receptor HER2,c-erb B2/neu protein,erbB-2,herstatin,neuroblastoma/glioblastoma derived oncogene homolog,p185erbB2,v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (neuro/glioblastoma derived oncogene homolog),v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian)
more info or order :
Cell Signaling Technology product webpage
company information
Cell Signaling Technology
3 Trask Lane
Danvers, MA 01923
info@cellsignal.com
www.cellsignal.com
8776162355
headquarters: USA
Established in Beverly, MA in 1999, Cell Signaling Technology (CST) is a privately-owned company with over 400 employees worldwide. We are dedicated to providing innovative research tools that are used to help define mechanisms underlying cell function and disease. Since its inception, CST has become the world leader in the production of the highest quality activation-state and total protein antibodies utilized to expand knowledge of cell signaling pathways. Our mission is to deliver the world's highest quality research tools that accelerate progress in biological research and personalized medicine.